In March of 2019, the S(+) stereoisomer of ketamine known as esketamine was approved through the FDA as a fast-acting antidepressant. It relieves the signs of despair inside 4 hours of use and these effects can final for so long as several weeks.In December 2013, the government of India, in reaction to mounting leisure use and using ketamine as bei… Read More